Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 689–696 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
AstraZeneca PLC IMFINZI (Durvalumab) +/- tremelimumab - (NEPTUNE) Lung cancer Phase 3 Trial Discontinued Intravenous Oncology
AstraZeneca PLC IMFINZI (Durvalumab) +/- tremelimumab - (EAGLE) Head & neck cancer Phase 3 Trial Discontinued Intravenous Oncology
AstraZeneca PLC IMFINZI (Durvalumab) +/- tremelimumab - (MYSTIC) Lung cancer Phase 3 Trial Discontinued Intravenous Oncology
AstraZeneca PLC FASENRA (benralizumab) - GALATHEA Chronic obstructive pulmonary disease (COPD) Phase 3 Trial Discontinued Subcutaneous Respiratory
AstraZeneca PLC LYNPARZA (olaparib) - SOLO 3 Third-line ovarian cancer Phase 3 Trial Completed Oral Oncology
AstraZeneca PLC Lanabecestat (AZD3293) - AMARANTH Early Alzheimer's disease Phase 3 Trial Discontinued Oral Neurology
AstraZeneca PLC AZD1222 (D8110C00001) COVID-19 vaccine Phase 3 Trial Discontinued Intramuscular COVID-19
AstraZeneca PLC IMFINZI (Durvalumab) +/- tremelimumab - (MYSTIC) Lung cancer Phase 3 Trial Discontinued Intravenous Oncology